Brief: Pelthos Therapeutics Acquires Xeglyze® Topical Treatment For Head Lice
05/01/2026 14:28
Jan 5 (Reuters) - Pelthos Therapeutics Inc PTHS.A: PELTHOS THERAPEUTICS ACQUIRES XEGLYZE® (ABAMETAPIR) TOPICAL TREATMENT FOR HEAD LICE PELTHOS THERAPEUTICS INC - BUYS XEGLYZE FOR $1.8 MILLION Source text: ID:nGNX6D2Tmf Further company coverage: PTHS.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pelthos Therapeutics
See all newsPelthos Therapeutics falls as co says will restate Q1 financial statements
Brief: Pelthos Therapeutics Financial Statements Should No Longer Be Relied Upon For Quarter Ended March 31- SEC Filing
Pelthos Therapeutics Q2 revenue rises on Zelsuvmi adoption
Brief: Pelthos Therapeutics Announces CFO Transition
Brief: Pelthos Therapeutics Announces First Patient Dosed In Phase 1B/2A Clinical Trial Of Ct2000 In Eye Pain